Akebia Therapeutics (AKBA) said Thursday that its Vafseo drug for anemia related to chronic kidney disease has been granted Transitional Drug Add-On Payment Adjustment, or TDAPA, reimbursement, effective Jan. 1, 2025, by the Centers for Medicare and Medicaid Services.
Vafseo is expected to be available in the market in January, according to Akebia. It was approved by the US Food and Drug Administration in March to treat anemia caused by chronic kidney disease in adults.
The TDAPA program provides reimbursement for Vafseo for the next two years on top of the bundled rate under the End-Stage Renal Disease prospective payment system, Akebia said.
The company also said it received a Level II Healthcare Common Procedure Coding System code for Vafseo that will be used by dialysis organizations for billing for Medicare enrollees.
Price: 1.3000, Change: +0.02, Percent Change: +1.56
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。